FDA Eliminates REMS for Carvykti and All BCMA-Directed CAR T in R/R MM

On June 27, 2025, the FDA removed the Risk Evaluation and Mitigation Strategy (REMS) requirement for all BCMA‑ and CD19‑targetedCAR‑T therapies, including Carvykti (ciltacabtagene autoleucel), significantly reducing access barriers in relapsed/refractory multiple myeloma (R/R MM).Previously, institutions required specialized certification, on-site availability of tocilizumab, and strict monitoring protocols. The move was supported by real-world safety data showing no increases in cytokine release syndrome (CRS) or significant neurotoxicity in post-commercial use. Under the new framework, Carvykti will continue to carry boxed warnings but rely on standard drug safety monitoring—simplifying REMS logistics. Oncology centers, especially community-based, stand to benefit from this reduction in administrative burden, potentially increasing patient eligibility and institutional participation in CAR‑T programs.

Citation: https://www.fda.gov/news-events/press-announcements/fda-eliminates-risk-evaluation-and-mitigation-strategies-rems-autologous-chimeric-antigen-receptor?utm_source=chatgpt.com

Implication:
By streamlining REMS compliance, the FDA enables broader deployment of Carvykti, favoring its competitive position versus Abecma and Elrexfio. Easier access could lead to earlier-line adoption and better uptake in non-academic settings—a significant strategic advantage.

‍